New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs for millions of people.

Galcanezumab shows similar pregnancy outcomes to placebo, highlighting the need for more real-world safety data in patients ...

Despite available treatments, over 50% of people currently using preventive medications still qualify for additional preventive therapy. Atogepant, marketed as AQUIPTA in the EU and QULIPTA in the U.S ...

The trial also showed superior efficacy for atogepant, with 64.1% of patients achieving at least a 50% reduction in monthly migraine days versus 39.3% for topiramate.

Company News Published 06/18/2025, 07:21 AM 0 AbbVie’s atogepant shows superior results in migraine prevention trial ABBV -0.77% ...

Qulipta/Aquipta shows superior tolerability: In the Phase III TEMPLE trial, only 12.1% of patients on Qulipta (atogepant) for the treatment of migraine headaches discontinued therapy due to adverse ...

But experiencing random dizzy spells throughout the day is nothing short of unnerving. The potential causes can range from something as innocuous as slacking on your hydration to an ear condition or ...

It is not for migraine prevention. It belongs to a group of drugs called gepants, which block a chemical in the brain called calcitonin gene-related peptide (CGRP) that’s involved in causing ...

Additionally, CT-132 was associated with improvements in quality of life and disability based on Migraine-Specific Quality of Life Questionnaire scores at weeks 4, 8, and 12 (P <.001 at all time ...

Migraine impacts millions worldwide, causing severe pain, nausea, and sensitivity to light and sound. While prescription medications may help, they aren’t the only option.

In regard to analyses of combined interventions, CBT plus relaxation training was less effective than propranolol alone for migraine prevention (-1.4 migraine days per month; 95% CI, -2.63 to -0.16).